BioSig Announces Abstract Acceptance to Computing in Cardiology 2020
14 sept. 2020 15h00 HE
|
BioSig Technologies, Inc.
Westport, CT, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Novel algorithm can successfully reconstruct ECG lead placementsThe method may improve the automated classification of patient conditions and unlock...
Reminder: BioSig to Host Conference Call and Webcast on September 15, 2020 to Discuss Unblinding of PURE EP Human Data
14 sept. 2020 10h29 HE
|
BioSig Technologies, Inc.
Westport, CT, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Peer-reviewed, blinded, randomized data recently presented at ESC Congress 2020Commercial market update discussionPresentation to include webcast ...
ViralClear to Host Conference Call on September 22, 2020, to Discuss Phase 2 Human Trial of AntiViral Merimepodib Oral Solution for Treatment of COVID-19
09 sept. 2020 12h15 HE
|
BioSig Technologies, Inc.
Westport, CT, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Randomized, Double-Blind, Placebo-Controlled, Clinical Trial of Merimepodib in Combination with Remdesivir in Hospitalized Adults with COVID-19 Who...
BioSig to Host Conference Call on September 15, 2020 to Discuss Unblinding of PURE EP Human Data
02 sept. 2020 10h15 HE
|
BioSig Technologies, Inc.
Peer-reviewed, blinded, randomized data recently presented at ESC Congress 2020Commercial market update discussion Westport, CT, Sept. 02, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc....
BioSig Technologies to Present at The LD 500 Virtual Conference
25 août 2020 08h30 HE
|
BioSig Technologies, Inc.
Westport, CT, Aug. 25, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing a proprietary biomedical signal...
Infectious Diseases Expert Prof. Angus Dalgleish Joins ViralClear’s Scientific Advisory Board
06 août 2020 10h00 HE
|
BioSig Technologies, Inc.
Westport, CT, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Expert in Infectious Diseases and Immune OncologyViralClear Pharmaceuticals is Currently in Phase 2 Trials with Merimepodib in the Fight Against...
ViralClear Appoints Dr. Michael Sofia to Its Scientific Advisory Board
05 août 2020 14h09 HE
|
BioSig Technologies, Inc.
Westport, CT, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Dr. Sofia is an Inductee in the American Chemical Society Medicinal Chemistry Hall of FameViralClear Pharmaceuticals is Currently in Phase 2 Trials...
BioSig Installs PURE EP(tm) System at Massachusetts General Hospital
04 août 2020 09h25 HE
|
BioSig Technologies, Inc.
Westport, CT, Aug. 04, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company developing a proprietary biomedical signal...
BioSig Awarded CAGE Code by the Systems for Award Management (SAM)
03 août 2020 14h00 HE
|
BioSig Technologies, Inc.
Westport, CT, Aug. 03, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing...
BioSig Technologies to Present at the Proactive Investors One2One Virtual Event on August 4, 2020
30 juil. 2020 13h00 HE
|
BioSig Technologies, Inc.
Westport, CT, July 30, 2020 (GLOBE NEWSWIRE) -- Update on the PURE EP(tm) System installations and commercial progressUpdate on Phase 2 clinical study of merimepodib in combination with remdesivir...